Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05034133

Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer

Limited Stage Small Cell Lung Cancer Clinical Trial

Official title:
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer: A Single-arm Phase II Trial.

Clinical Trial Summary

This is a single arm Phase II study, in which 6 cycles of durvalumab with chemotherapy (Etoposide and Cisplatin) and durvalumab followed by Sequential radiotherapy for limited stage small cell lung cancer.

Clinical Trial Description

Primary Outcome Measures: Progression free survival Secondary Outcome Measures: Overall survival Safety analysis ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05034133
Study type Interventional
Source Beijing Haidian Hospital
Contact Yuqing Huang, Director
Phone +8601082693152
Email huangyuqing555@gmail.com
Status Recruiting
Phase Phase 2
Start date September 1, 2021
Completion date August 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Recruiting NCT05443646 - Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients Phase 2
Completed NCT00066742 - Tirapazamine Combined With Chemo and RT in Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04790253 - PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study) N/A
Recruiting NCT05942508 - A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and Chemotherapy Phase 1
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Recruiting NCT05483543 - Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy Phase 2
Active, not recruiting NCT02046733 - Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease Phase 2
Completed NCT04952597 - Study of Ociperlimab Plus Tislelizumab Plus Chemoradiotherapy in Participants With Untreated Limited-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05623267 - Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT Phase 2/Phase 3
Completed NCT01457469 - Enhanced Quitline Intervention in Smoking Cessation for Patients With Non-Metastatic Lung Cancer Phase 1
Recruiting NCT06117774 - Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Phase 3
Completed NCT01999881 - Impacts of Exercise on Prognostic Biomarkers in Lung Cancer Patients N/A
Not yet recruiting NCT05496166 - The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer Phase 3
Recruiting NCT04829708 - Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cell Lung Cancer Who Achieved Remission After First-line Chemoradiotherapy Phase 3
Completed NCT00470054 - Dasatinib in Treating Patients With Relapsed Small Cell Lung Cancer Phase 2
Terminated NCT00084487 - Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy Phase 2
Recruiting NCT06256237 - Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial Phase 2